Details

Autor(en) / Beteiligte

• Dörner, Lorenz
• Grosse, Lucia
• Stange, Felix
• Hille, Hanni
• Kurz, Sylvia
• Becker, Hannes
• Volkmer, Sebastian
• Hippler, Melina
• Rieger, David
• Bombach, Paula
• Rieger, Johannes
• Weinert, Lina
• Svensson, Laura
• Anders, Carolin
• Cekin, Sila
• Paulsen, Frank
• Öner, Öznur
• Ruhm, Kristina
• Malek, Holly Sundberg
• Möller, Yonne
• Tatagiba, Marcos
• Wallwiener, Markus
• Eckert, Nils
• Escher, Pascal
• Pfeifer, Nico
• Forschner, Andrea
• Bauer, Armin
• Zips, Daniel
• Bitzer, Michael
• Malek, Nisar
• Gani, Cihan
• Tabatabai, Ghazaleh
• Renovanz, Mirjam

Titel

App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine—(TRACE)

Ist Teil von

• Neuro-oncology practice, 2024-06, Vol.11 (3), p.336-346

Ort / Verlag

US: Oxford University Press

Erscheinungsjahr

2024

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Abstract Background Biomarker-based therapies are increasingly used in cancer patients outside clinical trials. Systematic assessment of patient-reported outcomes (PRO) is warranted to take patients’ perspectives during biomarker-based therapies into consideration. We assessed the feasibility of an electronic PRO assessment via a smartphone application. Methods An interdisciplinary expert panel developed a smartphone application based on symptom burden and health-related quality of life (HRQoL) metrics reported in a retrospective analysis of 292 neuro-oncological patients. The app included validated assessments of health-related quality of life (HRQoL), the burden of symptoms, and psychological stress. Feasibility and usability were tested in a pilot study. Semi-structured interviews with patients and health care professionals (HCP) were conducted, transcribed, and analyzed according to Mayring´s qualitative content analysis. Furthermore, we assessed compliance and descriptive data of ePROs. Results A total of 14 patients have been enrolled, (9 female, 5 male). A total of 4 HCPs, 9 patients, and 1 caregiver were interviewed regarding usability/feasibility. The main advantages were the possibility to complete questionnaires at home and comfortable implementation in daily life. Compliance was high, for example, 82% of the weekly distributed NCCN distress thermometer questionnaires were answered on time, however, with interindividual variability. We observed a median distress score of 5 (range 0–10, 197 results, n = 12, weekly assessed) and a median Global health score of 58.3 according to the EORTC QLQ-C30 instrument (range 16.7–100, 77 results, n = 12, monthly assessed). Conclusions This pilot study proved the feasibility and acceptance of the app. We will therefore expand its application during biomarker-guided therapies to enable systematic PRO assessments.